Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.

Publikation

Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.

Wissenschaftlicher Artikel/Review - 12.12.2017

Weber Nina T, Sigaroudi Ali, Ritter Alexander, Boss Andreas, Lehmann Kuno, Goodman David, Farese Stefan, Weiler Stefan, Müller Thomas F

Zitation

Weber N, Sigaroudi A, Ritter A, Boss A, Lehmann K, Goodman D, Farese S, Weiler S, Müller T. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report. BMC Nephrol 2017; 18:360.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMC Nephrol 2017; 18

Veröffentlichungsdatum

12.12.2017

eISSN (Online)

1471-2369

Seiten

360

Kurzbeschreibung/Zielsetzung

Mycophenolic acid (MPA), either given as an ester pro-drug or as an enteric-coated sodium salt, is the most commonly prescribed anti-proliferative immunosuppressive agent used following organ transplantation and widely applied in immune-mediated diseases. Clinicians are well aware of common adverse reactions related to MPA treatment, in particular diarrhea, leukopenia and infections. Here we report a case of severe, persistent ascites associated with MPA treatment. The otherwise unexplained and intractable ascites, requiring repeated paracenteses for more than 8 months, rapidly ceased with stopping the MPA treatment. To our knowledge this is the first case of severe ascites associated with MPA treatment reported in the scientific literature.